Exenatide + Placebo
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Oct 1, 2010 → Dec 1, 2014
NCT ID
NCT01364584About Exenatide + Placebo
Exenatide + Placebo is a pre-clinical stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01364584. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01140893 | Phase 2/3 | UNKNOWN |
| NCT01364584 | Pre-clinical | Completed |
| NCT00845507 | Approved | Completed |
| NCT00603239 | Phase 3 | Completed |
| NCT00516074 | Phase 3 | Completed |
| NCT00500370 | Phase 2 | Completed |
| NCT00456885 | Approved | Completed |
| NCT00667732 | Approved | Completed |
| NCT00375492 | Phase 3 | Completed |
| NCT00324363 | Phase 3 | Completed |
| NCT00241423 | Phase 2 | Completed |
| NCT00099320 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes